Animal and in vitro models show that the combination of Eucommia, Cuscuta, and Drynaria can support bone health by reducing the prevalence of osteclasts, which contain bone dissolving proteins.
Photo © iStockphoto.com/Wavebreakmedia
A recent study1 found that the combination of Eucommia, Cuscuta, and Drynaria (EuBone from Chenland, based in Irvine, CA), which are widely used in traditional Chinese medicine, improved bone density, structural integrity, and biochemical function in rats with Glucocorticoid-induced osteoporosis (GIO). Administration also resulted in reduced urinal calcium, phosphorus loss, and decreased expression of RANKL (Receptor activator of nuclear factor kappa-Β ligand), CTX (cross-linked C-telopeptide of type I collagen) in serum, increased serum calcium, phosphorus, and OPG (Osteoprotegerin) level. In vitro, the combination reduced the prevalence of osteoclasts, which are bone dissolving proteins, pointing to the potential mechanism of action.
Given the promising results from in vitro and animal models Chenland is underway with a double-blind, placebo-controlled study on bone health in post-menopausal women, which is expected to be completed in 2023, and is planning a 180-day, single-center, open label human clinical study to investigate the effects of EuBone on elderly adults (especially women) with mild to moderate osteoporosis.
Reference
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.